

SPRING GROUP MEETING

# Seattle

# Prevention & Epidemiology Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

# Cancer Control & Prevention Committees

## Leadership

Vice-Chair NCORP: ..... Dawn L. Hershman, MD, MS  
 Cancer Care Delivery Co-Chairs: ..... Dawn L. Hershman, MD, MS  
 ..... Scott D. Ramsey, MD, PhD  
 Cancer Survivorship Co-Chairs: ..... Halle C.F. Moore, MD  
 ..... Melinda L. Irwin, PhD, MPH  
 Palliative & End of Life Co-Chairs: ..... Robert S. Krouse, MD, FACS  
 ..... Marie Bakitas, DNSc, CRNP  
 Prevention and Epidemiology Co-Chairs: ..... Banu Arun, MD  
 ..... Marian L. Neuhaus, PhD, RD  
 Symptom Control & QOL Co-Chairs: ..... Michael J. Fisch, MD, MPH  
 ..... Norah Lynn Henry, MD, PhD  
 Executive Officers: ..... Katherine D. Crew, MD (CCD, Prevention,  
 ..... Symptom Control)  
 ..... Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)  
 Senior Advisor: ..... Frank L. Meyskens, Jr., MD  
 Statisticians: ..... Katherine Guthrie, PhD  
 ..... Cathy Tangen, DrPH  
 ..... Joseph M. Unger, PhD  
 ..... Kathryn B. Arnold, MS  
 ..... Amy K. Darke, MS  
 ..... Danika Lew, MA  
 ..... Sarah Colby, MS  
 Administrative Lead SDMC: ..... Monica Yee, CCRP

## Scientific Leadership

NCORP Representative: ..... Scott Edward Delacrois, Jr., MD  
 ..... Helen Heng-Shan Moon, MD  
 Radiation Oncology: ..... Eileen P. Connolly, MD, PhD (CCD, Prevention)  
 ..... Kiri A. Cook, MD (Survivorship, Symptom Control)  
 ..... Erin F. Gillespie, MD (Symptom Control)  
 Surgery Committee: ..... Robert S. Krouse, MD, FACS  
 Translational Medicine: ..... James Rae, PhD  
 Liaisons:  
 Barlogie-Salmon Myeloma Committee: ..... Charles S. Kuzma, MD  
 Breast Committee: ..... Mariya Rozenblit, MD (Survivorship)  
 ..... Helen K. Chew, MD (Symptom Control)  
 ..... Dawn Hershman, MD, MS (CCD)  
 ..... Banu Arun, MD (Prevention)  
 ..... Philip Lammers, MD  
 Early Therapeutics & Rare Cancers: ..... Lara E. Davis, MD (Survivorship)  
 ..... Jason M. Prosek, MD  
 Gastrointestinal Committee: ..... Jason A. Zell, DO (Prevention)  
 ..... Afsaneh Barzi, MD (CCD)  
 Genitourinary Committee: ..... Clara Hwang, MD  
 ..... Sarah P. Psutka, MD

International Liaison: ..... Kathy S. Albain, MD  
 Leukemia Committee: ..... Stephanie B. Tsai, MD  
 Lung Committee: ..... Gary E. Goodman, MD  
 Lymphoma Committee: ..... Hayder Saeed, MD  
 Melanoma Committee: ..... Sancy Leachman, MD, PhD  
 ..... Thach-Giao Truong, MD (Survivorship)  
 Recruitment & Retention: ..... Allison M. Caban-Holt, PhD  
 Digital Engagement: ..... Jennifer R. Klemp, PhD (Survivorship)  
 ..... Krishna Soujanya Gunturu, MD (Survivorship)  
 ..... Mina S. Sedrak, MD (CCD)  
 ..... Katherine D. Crew, MD (Prevention)  
 ..... Michael J. Fisch, MD (Symptom Control)  
 Veterans Affairs: ..... Yeun-Hee Anna Park, MD (Symptom Control)  
 ..... Neha Patel, MD (Survivorship)  
 ..... Jacqueline Ann Gesek, BSN, RN (Nursing)

## Designates

### Oncology Research Professionals:

CRAs: ..... Amanda R. Dinsdale, MHA, CCRC  
 ..... Amy Jo Koffarnus, BS, CCRP  
 ..... Samantha Wright, MS, CCRP  
 ..... Shirley S. Sui, BS  
 Nurses: ..... Connie Szczepanek, RN, BSN  
 ..... Melyssa W. Foust, MSN, RN  
 Pharmaceutical Sciences Committee: ..... Kimberly McConnell, PharmD  
 ..... Siu-Fun Wong, PharmD  
 ..... Sun "Coco" Yang, PharmD, PhD  
 SDMC Data Coordinators: ..... Kimberly Carvalho, BA  
 ..... Sam Dzingile, BA  
 ..... Matthew Eng, PharmD  
 ..... Diane Liggett, BS, CCRP  
 ..... Roxanne Topacio, CCRP  
 ..... Monica Yee, BA, CCRP  
 Recruitment & Retention Specialist: ..... Jamie Sundstrom, BS  
 Patient Advocates: ..... Barbara Segarra-Vazquez, DHSc (CCD)  
 ..... Amy Geschwender, PhD (Symptom Control)  
 ..... Hartley "Lee" M. Jones, MBA (Survivorship)  
 ..... Cheryl L. Jernigan, CPA (Prevention)  
 ..... Valerie Fraser (Palliative)  
 Sr. Protocol Project Manager (CCD and Prevention): ..... Patricia O'Kane  
 Protocol Project Manager (Survivorship): ..... Megan Keim  
 Protocol Project Manager (Symptom Control): ..... Justine Trevino  
 Protocol Project Manager (Palliative Care): ..... Andrea Garcia  
 Clinical Trials Program Manager (Palliative Care): ..... Laura Gildner, MS  
 Clinical Trials Program Manager (CCD; Prevention;  
 Survivorship; Symptom Control): ..... Mariah Norman, MS



# Prevention & Epidemiology Committee

## Leadership

Co-Chairs: ..... Banu Arun, MD  
 ..... Marian L. Neuhouser, PhD, RD

## Time/Location

Thursday, April 4, 2024 12:30 p.m. - 2:30 p.m.  
 Room: Elwha AB (Level 5)

## Agenda

**Welcome and Opening Comments:** Dr. Marian Neuhouser &  
 Dr. Banu Arun

## Frank and Linda Meyskens Endowed Lectureship on Advances in Cancer Prevention

Inaugural Speaker: Dr. Gary Goodman

## Cancer Prevention Keynote Presentation

"The Cancer Screening Research Network: A New NCI-funded Initiative to Evaluate Emerging Technologies for Cancer Screening"

Dr. Scott Ramsey, Professor, Fred Hutchinson Cancer Center

Dr. Lori Minasian, Division of Cancer Prevention, National Cancer Institute

**Patient Advocate update** Cheryl Jernigan

## Active Studies

**S1823**, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20.

**S1904**, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20.

## Closed Studies

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

## Other Group Studies with SWOG Study Champions

**CTSUA151804**, "Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events." Dr. G. Lyman. Activated: 1/31/20.

**CTSUA212102**, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

**CTSUEA1151**, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. B. Arun. Activated: 7/6/17.

**CTSUNHLBI-MDS**, "The National Myelodysplastic Syndromes (MDS) Study." Drs. D. Hill and C. Arana Yi. Activated: 4/5/16.

**CTSUEA8184**, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

**CTSUNRG-CC005**, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

## Concept Reviewed by Cancer Prevention Steering Committee

**S2311**, Treatment Persistence with Alternate Doses of Exemestane or Tamoxifen among Postmenopausal Women with Atypical Hyperplasia, Lobular Carcinoma in situ or Hormone Receptor-Positive Ductal Carcinoma in situ. Dr. J. McGuinness.

## Studies approved by triage to be submitted for federal funding

## Potential amendments to existing or completed studies

**Amendment to S1007**, "Effects of Chemoprevention and Adjuvant Endocrine Therapy on a Convolutional Neural Network-Based Breast Cancer Risk Model Using Mammographic Datasets from S0812 and S1007." Drs. K. Crew, K. Kalinsky, R. Ha.

**Amendment to S1207**, "Effects of Adjuvant Endocrine Therapy on a Convolutional Neural Network (CNN)-Based Breast Cancer Risk Model Using Breast Imaging Datasets from S1207." Drs. K. Crew, J. McGuinness, R. Ha.

# Prevention & Epidemiology Committee

## Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

### Published/Accepted Manuscripts

None this cycle

### Submitted Manuscripts

S0000/Other Shedding light on the association between genetically-defined BMI and early-onset colorectal cancer in a pooled analysis. [Brief Communication], Archambault A, Gruber S, Le Marchand L, Hsu L, Peters U, Hayes R, (P Goodman C Tangen GECCO). Submitted 2023.

S0000/S9217 Long-term side effects and complications after prostate cancer treatment. Unger J, Till C, Tangen C, Hershman D, Goodman P, Leblanc M, Barlow W, Vaidya R, Minasian L, Parnes H, Thompson IM. Submitted, 2024.

# Prevention & Epidemiology Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
Ascension Providence Hospitals - Southfield	1	-	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	12	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	17	-	-	3	-	-
Banner MD Anderson Cancer Center	10	5	-	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	-	14	-	-	-	56	-	-	-	-
Baptist Mem. Health Care/Mid South Minority Underserved NCORP	4	-	10	-	-	8	-	-	-	-
Bay Area Tumor Institute NCORP	1	6	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	3	-	-	4
Brooke Army Medical Center	1	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	236	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	2	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	4	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	5	24	-	-	2	-	-	-	-
City of Hope Comprehensive Cancer Center	1	-	18	2	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	1	-	33	1	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	6	10	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	4	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	5	5	-	-	-	100	-	-	-	-
Georgia Cares Minority Underserved NCORP	2	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	13	-	-	-	-	-	-	-	1
Hawaii Minority Underserved NCORP	10	3	17	-	-	50	-	-	-	-
Heartland Cancer Research NCORP	2	14	9	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	4	133	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	40	156	10	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	3	-	-	-	-	-	-	-
Loma Linda University Medical Center	2	7	-	-	-	-	-	-	-	-
Loyola University Medical Center	2	-	3	-	-	-	-	-	-	-
Mass. Veterans Epidemiology Research and Information Center	3	-	-	-	15	-	8	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	4	-	-	-	-
Meharry Medical College	1	-	-	-	-	-	-	-	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	-	8	-	-	-	-
Mercy Medical Center - Des Moines	1	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	12	-	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	2	-	-	-	-	-	-	-	-	-

## Prevention & Epidemiology Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	460	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	2	11	-	-	-	-	-	-	-	-
Northwell Health NCORP	2	11	-	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	8	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	16	-	-	-	-	3	1	-	1
Pacific Cancer Research Consortium NCORP	2	-	1	-	-	-	-	-	-	-
Salem Hospital	-	3	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	2	-	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	1	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	33	3	-	-	10	-	-	-	-	-
UC San Diego Moores Cancer Center	-	23	-	-	-	-	1	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	30	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	32	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	381	3	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	5	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	8	24	-	-	5	2	-	-	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	9	-	-	-	-
University of Mississippi Medical Center	1	6	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	7	-	-	-	-	-	-	-	-
University of Rochester LAPS	-	18	-	-	-	263	-	-	-	-
University of Texas Health Science Center at San Antonio	9	-	-	-	14	-	-	-	-	1
University of Texas MD Anderson Cancer Center LAPS	5	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	21	-	-	-	-	-	-	-
Upstate Carolina Consortium Comm. Oncology Research Program	-	-	-	-	-	619	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	7	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	11	16	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	2	-	-	-	-	8	-	-	-	-
Western States Cancer Research NCORP	1	-	-	-	-	69	-	-	-	-
Wisconsin NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	25	-	-	-	-	-	-	-	-	-
ALLIANCE	37	86	98	-	-	-	-	-	-	-
CCTG	-	188	-	-	-	-	-	-	-	-
ECOG-ACRIN	34	69	36	-	-	-	-	-	-	-
NRG	38	51	69	-	-	-	-	-	-	-
<b>Total</b>	<b>354</b>	<b>877</b>	<b>352</b>	<b>3</b>	<b>66</b>	<b>2,409</b>	<b>18</b>	<b>4</b>	<b>1</b>	<b>8</b>

